Express Scripts Flies Past EPS, Revenue Estimates
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The company’s chairman/CEO said:
We are fully underway with the integration process and will continue to focus on lowering healthcare costs while improving health outcomes. As a result of our steadfast commitment to providing exemplary service and innovative offerings to clients and patients, we are experiencing strong retention rates.
Customer retention rates are running above 95%, which the company says is “consistent with historical norms.” The company also revised guidance for the full 2012 fiscal year, raising adjusted EPS to $3.60-$3.75. The consensus estimate had been for EPS of $3.53.
The addition of Medco skews many comparisons, but gross margins rose year-over-year from 7.1% to 7.8%, and EBITDA per adjusted claim rose 7% over the same period a year ago. Express Scripts has also signed a new multi-year pharmacy network agreement with Walgreen Co. (NYSE: WAG).
Shares are up about 5% in after-hours trading, at $58.84. The current 52-week range is $34.47-$59.50. Thomson Reuters had a consensus analyst price target of $66.10 before today’s results were announced.
Paul Ausick
Contact [email protected] for any questions or corrections.
